Immunotec named an official sponsor of Rowing Canada Aviron

VAUDREUIL-DORION, QC, December 3, 2013 – Immunotec Inc. (TSX VENTURE EXCHANGE: IMM), a Canadian based company and a leader in the wellness industry (the “Company”) and Rowing Canada Aviron (RCA) are pleased to announce a new partnership that sees Immunotec becoming an official sponsor and supplier of sport performance nutrition supplements to RCA’s National Team athletes as they strive towards podium success in Rio 2016. Immunotec, the producers of Immunocal® Platinum, was recommended by RCA’s nutritionists as part of an overall health and wellness plan.

“Optimizing recovery, performance and wellness in our athletes is crucial to their ability to achieve international success and Immunotec’s supplements play an important role towards this objective for many of our high performance athletes,” said RCA’s Nutritionist, Susan Boegman.

In addition to supplying the National Team with Immunocal Platinum and other nutritional products, Immunotec will also partner with RCA to launch a new program to assist developing clubs and coaches at the community level. Details of the program will be announced at RCA’s National Conference in January.

“We are delighted to be able to be partner with Rowing Canada in support of both their high performance and community level programs. Improving the athlete’s overall resiliency whether at the national level or club level will allow them to maximize their potential under the training protocols set forth by their coaches,” said John Molson, Immunotec Vice-President, Research and Development.

“This is a very beneficial partnership as it directly provides our athletes with a product of value as well as providing our clubs with the opportunity to learn from our internationally-renowned coaches,” said Donna Atkinson, Rowing Canada Aviron, Chief Executive Officer. “We have had a relationship for the past year, but this formal agreement boosts the partnership for both RCA and Immunotec.”

Rowing Canada Aviron represents members of all levels of the sport, and runs one of Canada’s most successful summer Olympic-sport programs. For more information on rowing in Canada and to find your local club, visit rowingcanada.org

About Immunotec Inc.

Immunotec Inc. is dedicated to making a positive difference in people’s health and lifestyle every day by offering research-driven nutritional products through its network of Independent Consultants worldwide. Immunotec’s products are led by the flagship brand, Immunocal. Immunocal is a unique, specially-formulated natural protein product that has been clinically
demonstrated and patented to optimize your immune system. Immunotec’s strength comes from its culture that emphasizes teamwork and entrepreneurial leadership by employees, consultants and research collaborators.

Headquartered with manufacturing facilities near Montreal, Canada, Immunotec Consultants generate nearly $50 Million in annual revenue. Please visit us at www.immunotec.com for additional information.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

John Molson Vice-President, Research and Development Immunotec Inc. (450) 510-4450.

Patrick Montpetit CPA; CA CF, Vice-President and Chief Financial Officer, Immunotec Inc. (450) 510-4527.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec’s most recent Management’s Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.